Potential Male Hair Loss Treatment Completes 26 Week Clinical Trial
A San Diego-based dermatological company has reached the completion date for its trial into the safety and efficacy of a product used on men with hereditary hair loss.
While no official announcement about the completion of the trial has yet been made, it is believed that Intrepid Therapeutics’ investigation into using a solution known as CB-03-01 on people with male pattern baldness finished in April. The study was first registered back in October 2014.
The company had been comparing a 5 per cent solution of a drug named CB-03-01, also known as Cortexolone 17α-Propionate, to the well-known hair loss drug Minoxidil in the trial, which also saw some participants given a placebo.
The researchers’ aims were to measure changes in the target area hair count, changes from baseline in the target area hair count, and also to see what test subjects thought of the treatment, with participants asked to rate their growth on a scale from -3 (greatly decreased hair growth) to +3 (greatly increased).
There is currently no information available about the team's findings, however as soon as their results are published we will post them here on the Belgravia blog.
The trial information at clinicaltrials.gov gives little away about CB-03-01, though it appears that a 1 per cent strength version of the drug has previously been trialled as a possible treatment for acne vulgaris. According to various internet reports, the drug “tightly mimics the profile of an ideal anti-androgen for topical use.”
It also appears that CB-03-01 is actually a molecule patented by an Italian pharmaceutical company named Cosmo, whose website confirms that it is “a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.”
Topical use means that the drug is applied directly to the skin, rather than being taken in pill form. When this option is available, many people prefer this route as they feel they are getting their medication to the exact spot it is needed. Side-effects associated with orally-taken drugs can sometimes be minimised in topical formulations, too.
Clinically-proven, MHRA licensed and FDA approved, high strength minoxidil formulations can be helpful in treating stubborn areas of hair loss in men and women, such as a receding hairline or thinning crown, promoting hair growth in these areas.
Furthermore, men may have the additional option of using finasteride 1mg which is taken once daily in pill form and should not be used topically to inhibit the cause of Male Pattern Baldness, the hormone byproduct DHT. This medication is not suitable for women.
A consultation with a specialist can help to ascertain recommendations as to the best suited hair loss treatments for the individual, as well as further information into how these products work.
While no official announcement about the completion of the trial has yet been made, it is believed that Intrepid Therapeutics’ investigation into using a solution known as CB-03-01 on people with male pattern baldness finished in April. The study was first registered back in October 2014.
Compared to Minoxidil
The company had been comparing a 5 per cent solution of a drug named CB-03-01, also known as Cortexolone 17α-Propionate, to the well-known hair loss drug Minoxidil in the trial, which also saw some participants given a placebo.
The researchers’ aims were to measure changes in the target area hair count, changes from baseline in the target area hair count, and also to see what test subjects thought of the treatment, with participants asked to rate their growth on a scale from -3 (greatly decreased hair growth) to +3 (greatly increased).
There is currently no information available about the team's findings, however as soon as their results are published we will post them here on the Belgravia blog.
The trial information at clinicaltrials.gov gives little away about CB-03-01, though it appears that a 1 per cent strength version of the drug has previously been trialled as a possible treatment for acne vulgaris. According to various internet reports, the drug “tightly mimics the profile of an ideal anti-androgen for topical use.”
It also appears that CB-03-01 is actually a molecule patented by an Italian pharmaceutical company named Cosmo, whose website confirms that it is “a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.”
Applied topically
Topical use means that the drug is applied directly to the skin, rather than being taken in pill form. When this option is available, many people prefer this route as they feel they are getting their medication to the exact spot it is needed. Side-effects associated with orally-taken drugs can sometimes be minimised in topical formulations, too.
Clinically-proven, MHRA licensed and FDA approved, high strength minoxidil formulations can be helpful in treating stubborn areas of hair loss in men and women, such as a receding hairline or thinning crown, promoting hair growth in these areas.
Furthermore, men may have the additional option of using finasteride 1mg which is taken once daily in pill form and should not be used topically to inhibit the cause of Male Pattern Baldness, the hormone byproduct DHT. This medication is not suitable for women.
A consultation with a specialist can help to ascertain recommendations as to the best suited hair loss treatments for the individual, as well as further information into how these products work.
The Belgravia Centre
The Belgravia Centre is a world-renowned group of a hair loss clinic in Central London, UK. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation from anywhere in the world for home-use treatment.
View our Hair Loss Success Stories, which includes the world's largest gallery of hair growth photos and demonstrates the level of success that so many of Belgravia's patients achieve.
